Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 -- 2628 2023-07-31 09:12:44 |
2 format correction Meta information modification 2628 2023-08-01 03:05:05 |

Video Upload Options

Do you have a full video?


Are you sure to Delete?
If you have any further questions, please contact Encyclopedia Editorial Office.
Cicekli, I.; Saglam, D.; Takar, N. Metabolic Syndrome with Osteopontin. Encyclopedia. Available online: (accessed on 25 June 2024).
Cicekli I, Saglam D, Takar N. Metabolic Syndrome with Osteopontin. Encyclopedia. Available at: Accessed June 25, 2024.
Cicekli, Ipek, Duygu Saglam, Nadir Takar. "Metabolic Syndrome with Osteopontin" Encyclopedia, (accessed June 25, 2024).
Cicekli, I., Saglam, D., & Takar, N. (2023, July 31). Metabolic Syndrome with Osteopontin. In Encyclopedia.
Cicekli, Ipek, et al. "Metabolic Syndrome with Osteopontin." Encyclopedia. Web. 31 July, 2023.
Metabolic Syndrome with Osteopontin

Metabolic syndrome (MetS) imposes a substantial burden on the healthcare systems and economies of countries and is a major public health concern worldwide. MetS is mainly caused by an imbalance between calorie intake and energy expenditure; however, it is recognized that additional variables, such as chronic inflammation, may have the same predictive potential as insulin resistance or MetS components in the genesis of type 2 diabetes and cardiovascular events. More importantly, the early diagnosis or treatment of MetS may significantly reduce the burden on the health systems of the disease with any prevention or biomarker and should not be underestimated. Osteopontin (OPN), also called secreted phosphoprotein 1, is a soluble protein found mostly in body fluids. Studies suggest that serum OPN levels may be an early and new biomarker to predict metabolic and cardiovascular complications significantly associated with some diseases.

metabolic syndrome osteopontin atherosclerosis hypertension

1. Introduction

MetS is mainly caused by an imbalance between calorie intake and energy expenditure [1]. MetS is diagnosed in the presence of at least three of these five risk factors: central obesity, fasting plasma glucose level ≥ 5.6 mmol/L, triglyceride level ≥ 1.7 mmol/L, HDL cholesterol level < 1.03 mmol/L in men and < 1.29 mmol/L in women, and elevated blood pressure [2]. However, it is also a complex pathophysiological process influenced by factors such as the genetic/epigenetic structure of the individual, a lifestyle with lack of movement, a quality and balanced diet, and intestinal microbiota. Unfortunately, it has become a global epidemic and there is no obvious solution to ending or mitigating this situation. The epidemic was not unforeseeable and could not be effectively contained; it can only be managed if there is a social will at that. As with other outbreaks, it will be crucial to inform and give education to individuals about the health risks of MetS [1].

2. Metabolic Syndrome and Osteopontin

2.1. Cornerstone 1: Atherosclerosis and Osteopontin

OPN is highly secreted from foam and macrophage cells of atherosclerotic plaques. In the clinical idea, OPN has been found to be related to numerous inflammatory diseases, including cardiovascular burden [3]. Due to the lower serum plasma level of OPN providing protection against post-myocardial infarction (MI) left ventricular dilation (by activating downstream signalling pathways such as mitogen-activated protein kinase, extracellular signal-regulated kinase, c-Jun N-terminal kinases, and the PI3K/Akt pathway) [4], it is thus crucial to dissect OPN anti-calcific and pro-inflammatory functions [3].
Calcification of the vessels, the most evident and dangerous sign of atherosclerosis, is a common occurrence in people with coronary artery disease (CAD) and vascular calcification is thought to be connected with an increased risk of MI [4]. According to a case-control study, OPN increases the risk of arterial calcification and the development of atherosclerotic plaques in arteries. Consequently, along with the induction of soft tissue biomineralization like the vascular wall, high serum levels of OPN have also been associated with CAD [5]. A study hypothesized that plasma levels of OPN, a new potential biomarker, are raised in patients with congestive heart failure and so this rise is also linked with disease projection and severity [6]. On the other hand, higher expression levels of OPN are found in vascular smooth muscle cells (VSMCs) in atherosclerotic plaques. In particular, apoptosis and VSMC migration are crucial markers of atherosclerosis progression. VSMC targeting strategies represent an effective method for discriminating delivery of anti-atherosclerotic drugs. The dominating role of OPN here is the ability of increasing inflammation in the atherosclerotic plaque and restricting vascular calcification which is involved in the atherosclerosis process. Furthermore, it has been shown that OPN correlated with the severity of CAD [7]. In another cardiac condition, heart failure, the role of OPN in calcification contributes to increased vascular resistance and ultimately to the development of disease [8]. As is already known, chronic congestive heart failure is a serious public health issue that is on the rise and with successful care relies on prompt and precise diagnoses, as well as simple risk stratification to identify patients who are most at risk of decompensation and death [6]. Despite the role of OPN in atherosclerosis-related pathways, little research has investigated whether OPN levels are linked to poor cardiovascular outcomes in individuals with established cardiovascular disease in this risk classification. As a matter of fact, plasma OPN levels have been independently linked with the composite incident endpoint of poor cardiovascular events (aOR: 2.04 1.44, 2.89) as well as incident hospitalization for heart failure (aOR: 2.04 1.44, 2.89) in patients with stable CAD [8]. Furthermore, by directing immunological response and VSMC migration, OPN has also been linked to atherosclerosis, neointima and plaque development, and dystrophic calcification. While enhanced OPN expression has the ability to defend against vascularization, it can also promote cardiac fibrosis and induce pathological remodelling through an increased extracellular matrix, collagen production, and deposition. This appears to be achieved by the stimulation of downstream signalling pathways [3]. Therefore, OPN levels may be an important therapeutic target in the atherosclerotic process. Serum OPN levels have been shown to be associated with cardiovascular events, but studies need to clarify the cut-off point of this biomarker. There are several studies that explore this cut-off point. One study separated all of the enrolled participants into three groups, assuming equal numbers of subjects per tertile, according to their baseline OPN levels: <2604 pg/mL (Tertile 1), 2605–4809 pg/mL (Tertile 2), and >4810 pg/mL (Tertile 3). According to the aforementioned study, OPN was an independent predictor of adverse cardiac outcomes in patients with chronic coronary syndrome, and an elevated OPN level was associated with a higher risk of acute myocardial infarction-related hospitalization (aOR: 3.20 1.23–8.33), particularly in those with OPN levels greater than 4810 pg/mL (Tertile 3). In addition, the combination of OPN and high-sensitivity-CRP indicated an increase in cardiac events [9]. However, no reference value for OPN has been reported in normal healthy populations or patients with CAD. However, because the research included patients with chronic coronary syndrome who had already undergone percutaneous coronary intervention, OPN levels in the study sample might be significantly higher [9]. Given that OPN levels were considerably higher in patients with heart failure and linked with functional status, Rosenberg et al. (2008) conducted a cohort study to determine the ideal OPN plasma level for prospective prediction of mortality within 48 months of follow-up. As a result, the optimum OPN cut-off value for predicting all-cause mortality after 48 months was 929 ng/mL, with a sensitivity of 46% and a specificity of 83% [6]. As stated in the study, OPN plasma levels were considerably higher in patients with systolic heart failure. Furthermore, it is hypothesized that OPN plasma levels may be used to predict outcomes independently of recognized clinical and biochemical indicators, such as N-terminal prohormone brain natriuretic peptide [6]. These findings imply that OPN is a new marker protein involved in the cardiac response to biomechanical load and myocardial damage [6]. Nevertheless, the best OPN cut-off value for predicting cardiovascular disease outcomes could not be clarified in the studies. Further research into the exact mechanisms of the dysregulated rise of OPN in chronic coronary syndrome patients are needed [9].

2.2. Cornerstone 2: Hypertension and Osteopontin

The vessel wall remodels in response to pulsatile flow and pressure increase. In hypertension, OPN expression is increased by a partial increase in aortic tension and an increase in reactive oxygen species production [10]. Activation of the phosphatidylinositol-3 kinase/Akt1 (known as protein kinase B) signalling pathway is one of the mechanisms by which mechanical strain increases OPN expression in VSMCs [11]. A peptide hormone Ang II that causes vasoconstriction and increases blood pressure, promotes hypertension and upregulates OPN expression particularly through Ang II in the production of reactive oxygen species [10].
OPN has been associated with hypertension-related inflammatory cell recruitment and vascular remodelling. Subsequently, the expressions of levels are significantly higher in aortic tissues and plasma in hypertensive rodents, and expression is positively correlated with systolic blood pressure [11] suggesting that OPN might be used as a new clinical marker for hypertension-induced vascular remodelling. One such study explains that treatment with statins and Ang II blockers significantly reduces plasma OPN levels [12]. Serum OPN levels are also favorably linked with arterial stiffness and significantly raised in arterial hypertension due to inflammatory factors that are amplified [5][13]. However, whether OPN affects peripheral monocyte differentiation and expression of inflammatory factors in hypertensive individuals with vascular calcification remains still unclear.
Ge et al. (2017) investigated if OPN regulates macrophage activation and osteoclast development in hypertensive patients with vascular calcification and it has been suggested that OPN-mediated macrophage activation plays a potential role in the regulation of hypertension-associated vascular calcification. Hypertensive patients with vascular calcification are characterized by a significantly increased peripheral proinflammatory monocyte ratio and increased serum OPN level when compared to hypertensive patients without vascular calcification. Most notably, the study shows that OPN modulates monocyte/macrophage phenotypic differentiation in hypertensive individuals with vascular calcification including attenuation of macrophage-osteoclast differentiation and inhibition of expression of inflammatory factors [14].
Stepien et al. (2011) found significant correlations between OPN levels and the inflammation marker c-reactive protein, but did not observe any correlation between fibrinogen and OPN. The study highlights the very strong association between hypertension and OPN levels (above 52 ng/mL). Inflammatory processes play key roles in endothelial dysfunction between hypertension and OPN levels. Interestingly, in the study it is also shown that risk factors such as gender, age, and diabetes mellitus had no significant effect of hypertension on raising OPN levels [13]. Additionally, a positive link between fasting glucose levels and OPN suggests that insulin resistance may upregulate the inflammatory process resulting in elevated CRP levels and impaired vascular function. Although CRP has not been identified as a determinant of serum OPN levels, it can be hypothesized that inflammation is a possible mechanism of endothelial dysfunction causing hypertension. The optimal cut-off point for OPN was determined to be 19.7 ng/mL to distinguish between hypertensive and asymptomatic subjects; however, the sensitivity and specificity of these tests are insufficient to employ OPN as the primary constructive tool for identifying endothelium impairment [13].

2.3. Cornerstone 3: Diabetes and Osteopontin

Pro-inflammatory cytokines, which play an important role in the development of diabetes complications, rise in response to OPN release [15]. The pathway is due to the fact that it is a multifunctional molecule that is selectively expressed in surrounding inflammatory cells in chronic inflammatory and autoimmune disorders. Furthermore, this biomarker is a secreted sticky molecule that is considered to help in monocyte-macrophage recruitment and control cytokine production in macrophages, dendritic cells, and T-cells. Therefore, OPN modulation of immune cell response has been linked to a variety of inflammatory conditions and may be crucial in the development of adipose tissue inflammation and insulin resistance [16]. In a study, high correlations of OPN levels with beta-cell function demonstrates the link between the inflammatory score and type 2 DM. A higher inflammatory score is associated with impaired beta-cell function, which is consistent with several studies that have shown that the histology of islets from patients with type 2 DM shows typical features of tissue inflammation, such as higher expression of cytokines and chemokines, immune cell infiltration, decreased insulin staining, cell apoptosis, and islet amyloidosis [17]. Another study discovered that plasma OPN levels correlated with the severity of diabetic nephropathy and CAD, implying that an elevated plasma OPN level might be utilized as a biomarker for screening diabetic vasculopathy [15]. As a result, it has been suggested that OPN plays an important role in the development of insulin resistance by enhancing macrophage accumulation in adipose tissue and encouraging inflammatory creation. These findings imply that OPN may play an important role in the development of insulin resistance by increasing inflammation and the recruitment of macrophages in adipose tissue [18].
Reducing circulating OPN levels is linked to improvements in blood pressure, LDL-c, HDL-c, and glycemic control. In a one-year follow-up study, serum OPN levels were found to be independent predictors of glycemic profile improvement. Glycemic improvement was seen in individuals who also reduced their circulating OPN levels. The study, thus, supposed that higher OPN levels at baseline indicate glycemic profile stabilization [19]. OPN has also been linked with diabetic retinopathy and nephropathy in patients with type 2 diabetes [20].
Daniele et al. suggested that plasma OPN levels in patients with type 2 DM were greater than in the control group in research on patients with type 2 DM and healthy controls. Another finding was a link between plasma OPN levels and tumor necrosis factor secretion, which mediates obesity-induced insulin resistance. It is revealed that hyperglycemia is also closely connected to the inflammatory state in type 2 diabetes. OPN might enhance the detection of low-grade inflammation in obese mice and patients with type 2 DM, as well as the prediction of abnormalities in glucose metabolism [21]. Although there are studies which have established a relationship between OPN levels and type 2 DM [20][21] and insulin resistance [22], studies on type 1 DM are insufficient. In the pediatric population with type 1 diabetes, elevated levels of OPN are related to poor metabolic control as evaluated by glycated hemoglobin and preclinical atherosclerosis [23]. In another study conducted with adults with type 1 diabetes, serum OPN is a robust predictor of incipient diabetic nephropathy and all-cause death [23]. These findings imply that OPN may play an important role in the development of insulin resistance by increasing inflammation and the recruitment of macrophages in adipose tissue [18]. However, more studies are needed to elucidate its effect on the pathogenesis of diabetes, especially type 1 DM. The fact that there are very few studies with type 1 DM indicates that there is a significant gap in the literature in this area.
Studies showed that serum OPN is independently associated with MetS. Serum OPN can be potentially used as a biochemical parameter for risk stratification of MetS [24].

2.4. Cornerstone 4: Obesity and Osteopontin

Chapman et al. (2010) showed that OPN depletion protects against metabolic impairment after only two weeks of feeding with a high-fat diet [22]. Despite a higher caloric intake, OPN depletion prevents the increase in body weight and adipose tissue expansion caused by a high-fat diet, as well as decreasing macrophage inflammation, infiltration, fibrosis, and oxidative stress [25].
Gómez-Ambrosi et al. (2007) highlighted that plasma OPN concentrations are significantly higher in people who are overweight or with obesity and circulating OPN concentrations correlate with body fat. Moreover, OPN mRNA and protein are expressed in omental adipose tissue and this expression is increased in obesity and further elevated in obesity-associated type 2 DM. Finally, modest diet-induced weight loss is accompanied by a significant decrease in plasma OPN levels [26]. In the aforementioned study, patients with obesity had a two-fold rise in plasma OPN concentrations compared to lean people. A substantial positive association was demonstrated in the study between OPN and body fat, indicating that OPN levels are connected to the quantity of adipose tissue [26]. The decrease in OPN plasma concentrations reported in people with obesity following weight loss may contribute to a lower cardiovascular risk profile. Therefore, a drop in OPN levels may contribute to the decrease in cardiovascular morbidity reported following weight loss [26].
As a consequence of morbid obesity, bariatric surgery procedure is an important route. Studies examining OPN levels in bariatric surgery patients discovered surprising findings in severely obese patients before and after bariatric surgery. Subjects who had previously had gastric banding or Roux-en-Y gastric bypass had lower body weight, BMI, inflammatory markers, and insulin resistance. All studies, however, uniformly documented a steady rise in OPN blood concentrations following bariatric surgery [27][28].
Consequently, results show that monocytes and macrophages not only respond to OPN and migrate to areas of inflammation, but they also survive and multiply more in the presence of OPN, confirming the established mechanism. Subsequently, secreted OPN appears to be a crucial participant in inflammation, not only by promoting monocyte chemotaxis and macrophage differentiation but also by promoting macrophage local proliferation [29]. As a result of the relationship between obesity and diabetes, obesity is now recognized to contribute to insulin resistance through persistent low-grade inflammation arising from visceral adipose tissue, which raises the chance of developing diabetes. Early identification of serum circulating molecules, particularly OPN, might be a promising technique for early diagnosis and, ultimately, preventing or delaying both diabetes and obesity effects [30].


  1. Saklayen, M.G. The Global Epidemic of the Metabolic Syndrome. Curr. Hypertens. Rep. 2018, 20, 12.
  2. Grundy, S.M.; Brewer, H.B., Jr.; Cleeman, J.I.; Smith, S.C., Jr.; Lenfant, C. Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109, 433–438.
  3. Mohamed, I.A.; Gadeau, A.-P.; Hasan, A.; Abdulrahman, N.; Mraiche, F. Osteopontin: A Promising Therapeutic Target in Cardiac Fibrosis. Cells 2019, 8, 1558.
  4. Icer, M.A.; Gezmen-Karadag, M. The multiple functions and mechanisms of osteopontin. Clin. Biochem. 2018, 59, 17–24.
  5. Tousoulis, D.; Siasos, G.; Maniatis, K.; Oikonomou, E.; Kioufis, S.; Zaromitidou, M.; Paraskevopoulos, T.; Michalea, S.; Kollia, C.; Miliou, A.; et al. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease. Int. J. Cardiol. 2013, 167, 1924–1928.
  6. Rosenberg, M.; Zugck, C.; Nelles, M.; Juenger, C.; Frank, D.; Remppis, A.; Giannitsis, E.; Katus, H.A.; Frey, N. Osteopontin, a New Prognostic Biomarker in Patients With Chronic Heart Failure. Circ. Heart Fail. 2008, 1, 43–49.
  7. Berezin, A.; Kremzer, A. Circulating osteopontin as a marker of early coronary vascular calcification in type two diabetes mellitus patients with known asymptomatic coronary artery disease. Atherosclerosis 2013, 229, 475–481.
  8. Abdalrhim, A.D.; Marroush, T.S.; Austin, E.E.; Gersh, B.J.; Solak, N.; Rizvi, S.A.; Bailey, K.R.; Kullo, I.J. Plasma Osteopontin Levels and Adverse Cardiovascular Outcomes in the PEACE Trial. PLoS ONE 2016, 11, e0156965.
  9. Cheong, K.-I.; Leu, H.-B.; Wu, C.-C.; Yin, W.-H.; Wang, J.-H.; Lin, T.-H.; Tseng, W.-K.; Chang, K.-C.; Chu, S.-H.; Yeh, H.-I.; et al. The clinical significance of osteopontin on the cardiovascular outcomes in patients with stable coronary artery disease. J. Formos. Med. Assoc. 2023, 122, 328–337.
  10. Caesar, C.; Lyle, A.N.; Joseph, G.; Weiss, D.; Alameddine, F.M.F.; Lassègue, B.; Griendling, K.K.; Taylor, W.R. Cyclic Strain and Hypertension Increase Osteopontin Expression in the Aorta. Cell. Mol. Bioeng. 2017, 10, 144–152.
  11. Seo, K.W.; Lee, S.J.; Ye, B.H.; Kim, Y.W.; Bae, S.S.; Kim, C.D. Mechanical stretch enhances the expression and activity of osteopontin and MMP-2 via the Akt1/AP-1 pathways in VSMC. J. Mol. Cell. Cardiol. 2015, 85, 13–24.
  12. Lorenzen, J.M.; Neunhöffer, H.; David, S.; Kielstein, J.T.; Haller, H.; Fliser, D. Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension—Results from the EUTOPIA trial. Atherosclerosis 2010, 209, 184–188.
  13. Stępień, E.; Wypasek, E.; Stopyra, K.; Konieczyńska, M.; Przybyło, M.; Pasowicz, M. Increased levels of bone remodeling biomarkers (osteoprotegerin and osteopontin) in hypertensive individuals. Clin. Biochem. 2011, 44, 826–831.
  14. Ge, Q.; Ruan, C.-C.; Ma, Y.; Tang, X.-F.; Wu, Q.-H.; Wang, J.-G.; Zhu, D.-L.; Gao, P.-J. Osteopontin regulates macrophage activation and osteoclast formation in hypertensive patients with vascular calcification. Sci. Rep. 2017, 7, 40253.
  15. Yan, X.; Sano, M.; Lu, L.; Wang, W.; Zhang, Q.; Zhang, R.; Wang, L.; Chen, Q.; Fukuda, K.; Shen, W. Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus. Cardiovasc. Diabetol. 2010, 9, 70.
  16. Kahles, F.; Findeisen, H.M.; Bruemmer, D. Osteopontin: A novel regulator at the cross roads of inflammation, obesity and diabetes. Mol. Metab. 2014, 3, 384–393.
  17. Velloso, L.A.; Eizirik, D.L.; Cnop, M. Type 2 diabetes mellitus—An autoimmune disease? Nat. Rev. Endocrinol. 2013, 9, 750–755.
  18. Nomiyama, T.; Perez-Tilve, D.; Ogawa, D.; Gizard, F.; Zhao, Y.; Heywood, E.B.; Jones, K.L.; Kawamori, R.; Cassis, L.A.; Tschöp, M.H.; et al. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J. Clin. Investig. 2007, 117, 2877–2888.
  19. Caserza, L.; Casula, M.; Elia, E.; Bonaventura, A.; Liberale, L.; Bertolotto, M.; Artom, N.; Minetti, S.; Contini, P.; Verzola, D.; et al. Serum osteopontin predicts glycaemic profile improvement in metabolic syndrome: A pilot study. Eur. J. Clin. Investig. 2020, 51, e13403.
  20. Yamaguchi, H.; Igarashi, M.; Hirata, A.; Tsuchiya, H.; Sugiyama, K.; Morita, Y.; Jimbu, Y.; Ohnuma, H.; Daimon, M.; Tominaga, M.; et al. Progression of diabetic nephropathy enhances the plasma osteopontin level in type 2 diabetic patients. Endocr. J. 2004, 51, 499–504.
  21. Daniele, G.; Mendoza, R.G.; Winnier, D.; Fiorentino, T.V.; Pengou, Z.; Cornell, J.; Andreozzi, F.; Jenkinson, C.; Cersosimo, E.; Federici, M.; et al. The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol. 2013, 51, 123–131.
  22. Chapman, J.; Miles, P.D.; Ofrecio, J.M.; Neels, J.G.; Yu, J.G.; Resnik, J.L.; Wilkes, J.; Talukdar, S.; Thapar, D.; Johnson, K.; et al. Osteopontin Is Required for the Early Onset of High Fat Diet-Induced Insulin Resistance in Mice. PLoS ONE 2010, 5, e13959.
  23. El-Asrar, M.A.; Ismail, E.A.R.; Thabet, R.A.; Kamel, A.S.; NehmedAllah, S. Osteopontin as a marker of vasculopathy in pediatric patients with type 1 diabetes mellitus: Relation to vascular structure. Pediatr. Diabetes 2018, 19, 1107–1115.
  24. De Fusco, C.; Messina, A.; Monda, V.; Viggiano, E.; Moscatelli, F.; Valenzano, A.; Esposito, T.; Sergio, C.; Cibelli, G.; Monda, M.; et al. Osteopontin: Relation between Adipose Tissue and Bone Homeostasis. Stem Cells Int. 2017, 2017, 4045238.
  25. Lancha, A.; Rodríguez, A.; Catalán, V.; Becerril, S.; Sainz, N.; Ramírez, B.; Burrell, M.A.; Salvador, J.; Frühbeck, G.; Gómez-Ambrosi, J. Osteopontin deletion prevents the development of obesity and hepatic steatosis via impaired adipose tissue matrix remodeling and reduced inflammation and fibrosis in adipose tissue and liver in mice. PLoS ONE 2014, 9, e98398.
  26. Gomez-Ambrosi, J.; Catalan, V.; Ramírez, B.; Rodríguez, A.; Colina, I.; Silva, C.; Rotellar, F.; Mugueta, M.D.C.; Gil, M.J.; Cienfuegos, J.; et al. Plasma Osteopontin Levels and Expression in Adipose Tissue Are Increased in Obesity. J. Clin. Endocrinol. Metab. 2007, 92, 3719–3727.
  27. Riedl, M.; Vila, G.; Maier, C.; Handisurya, A.; Shakeri-Manesch, S.; Prager, G.; Wagner, O.; Kautzky-Willer, A.; Ludvik, B.; Clodi, M.; et al. Plasma Osteopontin Increases After Bariatric Surgery and Correlates with Markers of Bone Turnover But Not with Insulin Resistance. J. Clin. Endocrinol. Metab. 2008, 93, 2307–2312.
  28. Komorowski, J.; Jankiewicz-Wika, J.; Kolomecki, K.; Cywinski, J.; Piestrzeniewicz, K.; Swiętoslawski, J.; Stepien, H. Systemic blood osteopontin, endostatin, and E-selectin concentrations after vertical banding surgery in severely obese adults. Cytokine 2011, 55, 56–61.
  29. Tardelli, M.; Zeyda, K.; Moreno-Viedma, V.; Wanko, B.; Grün, N.G.; Staffler, G.; Zeyda, M.; Stulnig, T.M. Osteopontin is a key player for local adipose tissue macrophage proliferation in obesity. Mol. Metab. 2016, 5, 1131–1137.
  30. Aztatzi-Aguilar, O.G.; Sierra-Vargas, M.P.; Ortega-Romero, M.; Jiménez-Corona, A.E. Osteopontin’s relationship with malnutrition and oxidative stress in adolescents. A pilot study. PLoS ONE 2021, 16, e0249057.
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to : , ,
View Times: 163
Revisions: 2 times (View History)
Update Date: 01 Aug 2023
Video Production Service